AMGEN Inc

NASDAQ: AMGN
$301.44
+$2.60 (+0.9%)
Closing Price on November 13, 2024

AMGN Articles

Wednesday's top analyst upgrades and downgrades included Advanced Micro Devices, Amgen, DexCom, eBay, FireEye, Kraft Heinz, 3M, Pfizer, Seagate Technology, Sonos, Starbucks and T-Mobile.
The July 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
Goldman Sachs has seven biopharma stocks on its Conviction Buy list, and these are not all coronavirus plays. The firm thinks these stocks could go on the offensive for the rest of the year.
These four top Jefferies growth stock picks all offer investors strength in their specific industries and the ability to generate some significant portfolio alpha.
Many investors feel like the key stocks in the market have simply gotten away from them, but those fears are perhaps misguided, according to some key analysts.
Stocks were looking for direction on Monday ahead of this week’s earnings deluge. With an election coming up and with what is still a very deep recession, investors need to be considering how they...
The June 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The June 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The May 29 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The May 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks was mixed.
The April 30 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Apple borrowed $8.5 billion Monday in a four-part bond deal. Why? Because right now, money is cheap.
The April 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The March 31 short interest data has been compared with the previous report, and short interest in these selected biotech stocks shrank.